Our Investments

Newton Biocapital's mission is to generate substantial financial and societal value by providing innovative, breakthrough, and affordable solutions to patients.

Dim3

DIM3 (Disease in management at the 3rd dimension) is a digital healthcare company co-founded in 2012, whose mission is to develop an application to monitor and improve enteral and parenteral nutrition. The company addresses a huge medical need in a space where awareness is currently low.

http://www.dim3.com
Epics Logo

EPICS THERAPEUTICS is developing first-in-class drugs in oncology based on RNA epigenetics. The company focuses on discovery and development of small molecule inhibitors of RNA-modifying enzymes to treat cancer.

Syngergia Medical

SYNERGIA is developing a next-generation, small-form, MRI-safe, implanted neurostimulation device for drug-resistant epilepsy, with a range of further therapeutic applications.

http://www.synergia-medical.com
Chromacure

ChromaCure is seeking to discover and develop first-in-class small molecule therapeutics for unmet needs in oncology. The company will develop inhibitors of a novel target that is a key regulator of tumor initiation and progression.

Logo Acticor

Acticor Biotech is a clinical stage biotechnology company, spin-off of INSERM, dedicated to developing an innovative treatment in the therapy of acute thrombotic diseases, including ischemic stroke and pulmonary embolism. Acticor Biotech is built upon the expertise and the results of researches conducted by, the founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Pr. Philippe Billiald at Paris-Sud University.

https://acticor-biotech.com/
Sequana Medical

Sequana Medical is a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders.

https://www.sequanamedical.com
Logo E4Th基本ロゴ

EditForce developed a unique DNA/RNA editing technology, based on pentatricopeptide repeat (PPR) protein platform technology. The technology has a distinct feature that enables the editing of not only DNA but also RNA, highlighting its difference compared to other technologies, and is thus expected to be applied to a wide range of fields. The platform technology has also different mechanisms to work and isolated IP from other existing DNA editing technologies.

https://www.editforce.co.jp/en/
Screen Shot 2020 08 14 At 14 48 43

Established in December of 2005, J-Pharma’s mission is to help mankind by creating and developing novel pharmaceuticals based upon a human-genomic approach; an approach where people with specific diseases are treated with novel and selective agents. J-Pharma’s intellectual property (IP) embraces the notion that cell membrane transporters are tightly associated to many diseases. In addition to drug molecules that target specific transporters, J-Pharma has discovered several important drug transporters within the human body that may be used to evaluate and optimize pharmacokinetics of new drug candidates. We believe that J-Pharma’s pipelines will lead to new agents and processes (i.e. diagnostic methods) and will increase the quality of life for an ageing population in industrialized countries. J-Pharma’s overall goal is to contribute globally to the maintenance of human health and improve human welfare through the creation of new drugs.

http://www.j-pharma.com/index_e.php
Schermafbeelding 2020 11 14 Om 15 58 56

Aboleris Pharma is developing new immunomodulators for immune mediated diseases. The company has two programs: 1) a monoclonal antibody anti-CD45RC (ABIS-45RC) and 2) the cytokine IL-34 (ABIS-34).

http://aboleris-pharma.com
Afbeelding1

Metabolys is developing a small molecule to treat patients suffering from metabolic diseases, especially Non Alcoholic Steato-Hepatitis (NASH). This small molecule (MTBL0036) targets the mitochondrial pyruvate carrier (MPC). Pyruvate lies at a central biochemical node connecting carbohydrate, amino acid, and fatty acid metabolism, and the regulation of pyruvate flux into mitochondria represents a critical step in intermediary metabolism impacting numerous diseases. With the first preclinical data generated by the company, the MTBL0036 seems to be the most efficient of all the orally active anti-NASH and antifibrotic candidates in development when assessed with the STAM animal model of NASH. Easy to produce, it seems to be very efficacious for inhibiting both inflammation and liver cell destruction and could potentially be used complementary of other anti-NASH candidates.